Résultats de recherche - Portail des modèles médicaux de données (portail MDM)

GSK AVA100193 Rosiglitazone in Alzheimer´s Disease - Pharmacogenetic and Pharmacogenomic Research - Pharmacogenetic and Pharmacogenomic Research

- 25/09/2017 - 1 Formulaire, 1 Groupe Item, 10 Eléments de données, 1 Langue

Groupe Item: PGx-Pharmacogenetic/PGm-Transcriptomic/PGM-Proteomic Research

A 24 week double-blind, randomised, placebo-controlled, parallel-group dose-ranging study to investigate the effects of rosiglitazone (extended release tablets) on cognition in subjects with mild to moderate Alzheimer's disease.

GSK Ropinirole in Subjects with Restless Legs Syndrome 101468/191 Week 12 Day (Form 16)

- 01/09/2017 - 1 Formulaire, 6 Groupes Item, 17 Eléments de données, 1 Langue

Groupes Item: General Information, Investigational Product Record since last visit, RSL Rating Scale, Vital Signs, Laboratory Evaluation, Pregnancy Dipstick

Study ID: 101468/191 Clinical Study ID: SKF-101468/191 Study Title:A 12 Week, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Ropinirole in Subjects with Restless Legs Syndrome (RLS) Suffering from Periodic Leg Movements of Sleep (PLMS) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Requip Study Indication: Restless Legs Syndrome

GSK Ropinirole in Subjects with Restless Legs Syndrome 101468/191 Baseline (Form 2)

- 31/08/2017 - 1 Formulaire, 13 Groupes Item, 59 Eléments de données, 1 Langue

Groupes Item: General Information, Orthostatic Vital Signs, Baseline PLMI, Polysomnography, Baseline Inclusion Criteria, Baseline Exclusion Criteria, RLS rating scales, Vital signs, Concomitant Medication, Medical Procedures, Baseline Signs and Symptoms, Baseline Employment Status, Ramos Randomization and dispensing

Study ID: 101468/191 Clinical Study ID: SKF-101468/191 Study Title:A 12 Week, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Ropinirole in Subjects with Restless Legs Syndrome (RLS) Suffering from Periodic Leg Movements of Sleep (PLMS) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Requip Study Indication: Restless Legs Syndrome

GSK Study: Evaluation of safety and efficacy of VarilrixTM and of Combined Measles-Mumps-Rubella-Varicella Vaccine NCT00226499 - Visit 3 and Guardians contact for rash

- 20/08/2017 - 1 Formulaire, 7 Groupes Item, 25 Eléments de données, 1 Langue

Groupes Item: Check for study continuation, Laboratory tests, Household exposure, Household exposure number, Varicella or zoster, Parents/Guardians contact for rash, Parents/Guardians contact for rash

GSK Study: Evaluation of safety and efficacy of VarilrixTM and of Combined Measles-Mumps-Rubella-Varicella Vaccine NCT00226499 - Visit 3 - Day 84 and Parents/ Guardians contact for rash Study ID: 100388 Clinical Study ID: 100388 Study Title: Study in Healthy Children (<2 Years) to Evaluate the Safety and Efficacy of GSK Biologicals' Live Attenuated Varicella Vaccine (VarilrixTM) and of GSK Biologicals' Combined Measles-Mumps-Rubella-Varicella Vaccine Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00226499 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: Varicella Vaccine Trade Name: BIO OKAH; Varilrix Study Indication: Varicella

GSK study: Ropinirole in RLS patients 101468/243 - Week 52

- 30/07/2017 - 1 Formulaire, 10 Groupes Item, 18 Eléments de données, 1 Langue

Groupes Item: Study medication record since last visit, RLS Rating scale, Vital signs, Laboratory test, Urine dipstick, Pregnancy dipstick, Medical procedures, Concomitant Medication, Adverse reaction, Clinical global impression

Part 1 of Module 12: Wk 52, Follow-Up & Study Conc 101468/243 Study ID: 101468/243 Clinical Study ID: 101468/243 Study Title: A 52 Week Open-Label Extension Study of the Long-Term Safety of Ropinirole in Subjects Suffering from Restless Legs Syndrome (RLS) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: N/A Sponsor:GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Modutab,ZIPEREVE,ZEPREVE,REPREVE,ADARTREL,REQUIP,Zygara; Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL Study Indication: Restless Legs Syndrome